drugset / Trial / NCT04893187
A Phase 1 Study of SSS17 in Healthy Subjects.
Phase 1
Unknown
76 enrolled
Shenyang Sunshine Pharmaceutical Co., LTD.
Fifth Affiliated Hospital of Guangzhou Medical University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of single oral administration of 5 mg, 15 mg, 20 mg and 25 mg of SSS17 compared with placebo, and evaluate the efficacy, safety, tolerance, pharmacokinetics and pharmacodynamics of multiple oral administration of 15 mg and 20 mg of SSS17 compared with placebo. In addition, the study will assess the effect of food on the pharmacokinetics of SSS17.
Timeline
- Start
- 2021-07-26
- Primary completion
- 2022-12-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SSS17 | Small molecule | 5 mg | Oral |
| Subject | SSS17 | Small molecule | 15 mg | Oral |
| Subject | SSS17 | Small molecule | 20 mg | Oral |
| Subject | SSS17 | Small molecule | 25 mg | Oral |